SMNR Semnur Pharmaceuticals Inc.
Financings ·
Semnur, a majority-owned subsidiary of Scilex, said iHolding Group LLP would buy $100,000,000 of newly issued common stock at an expected $10.00 per share. The proposal remains subject to due diligence and definitive agreements.
Semnur ended a private placement agreement with JW Capital Securities Limited and a share purchase agreement with Biconomy PTE. Ltd. Neither agreement had produced any issued shares.
Denali Capital filed a Form 12b-25 notice on August 14, 2025 saying it cannot file its June 30, 2025 quarterly report on time, because it is still completing its financial statements. The notice says the report will come no later than the fifth calendar day after the due date.
Denali Capital deposited $874.78 into its trust account to extend its deadline by one month, to August 11, 2025. The blank-check company's units, shares and warrants now trade on the Pink market and the OTCQB, and it remains a shell company that depends on monthly extensions.
Nasdaq staff said Denali Capital Acquisition Corp. had not regained compliance with its $50.0 million market value and total assets rules and also failed the public float rule. The blank-check company's securities will be delisted unless it appeals by April 9, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $2.5 million | $1.7 million |
| Net income (loss) | -$160.4 million | -$4.7 million |
| Cash from operations | -$5.9 million | -$4.9 million |
| Cash and equivalents | $20,000 | $12,000 |
Our latest story on this, dated Apr 9, 2025: "Nasdaq moves to delist Denali Capital (now Semnur Pharmaceuticals), the Semnur SPAC". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 20, 2026: "Semnur terminates two share purchase agreements tied to its 2025 merger". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Apr 20, 2026: "Semnur terminates two share purchase agreements tied to its 2025 merger". The story links the filing or release it is based on. Read the story.
Semnur Pharmaceuticals Inc. trades under the ticker SMNR on OTC.
Semnur Pharmaceuticals Inc. is listed on OTC.
The SEC Central Index Key (CIK) for Semnur Pharmaceuticals Inc. is 1913577. Its filings are on SEC EDGAR.
230,209,142 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-10.
Our directory records Semnur Pharmaceuticals Inc. under United States.
Our directory classifies Semnur Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Semnur Pharmaceuticals Inc. is US81686G1058.
aibio.space lists Semnur Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Semnur Pharmaceuticals Inc. reported a net loss of $160.4 million for the fiscal year ended Dec 31, 2025, and used $5.9 million of cash in operations, per its annual report to the SEC.
$2.5 million in the fiscal year ended Dec 31, 2025, per its annual report.
$39,000 in cash at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.01,2.03,3.02,3.03,4.01,5.01,5.02,5.03,5.05,5.06,7.01,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Filed to remove its shares from exchange listing. SEC Form 25-NSE. Source
Reported a merger or acquisition agreement. SEC Form 425. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a merger or acquisition agreement. SEC Form 425. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Filed documents for a merger or acquisition. SEC Form S-4. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio